Published in Medical Letter on the CDC and FDA, March 11th, 2007
"Compared with infused 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4), overall survival and progression-free survival are significantly longer with FOLFOX-4 in combination with bevacizumab as second-line...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA